Literature DB >> 3749442

Prognostic indicators in idiopathic IgA mesangial nephropathy.

G D'Amico, L Minetti, C Ponticelli, G Fellin, F Ferrario, G Barbiano di Belgioioso, E Imbasciati, A Ragni, S Bertoli, G Fogazzi.   

Abstract

Univariate survivorship analysis of a cohort of 365 patients with idiopathic IgA mesangial nephropathy and at least one year of further observation since the apparent onset (mean = 7.79 +/- 6.19 years; median = 6.16 years) has been performed. Observations for at least one year (mean = 5.05 +/- 3.66; median = 4.08 years) after biopsy was available for 292 of these. One immunohistological, four clinical, and six histological features were associated with increased risk of developing renal failure: (i) older at onset; (ii) no history of recurrent macroscopic haematuria; (iii) proteinuria of more than 1 g/day; (iv) arterial hypertension at the time of biopsy; (v) extent of glomerular obsolescence; (vi) extent of segmental glomerulosclerosis; (vii) presence of interstitial fibrosis; (vii) presence of diffuse intracapillary proliferation; (ix) presence of extracapillary proliferation; (x) presence of segmental thickening of glomerular basement membrane; (xi) extension of IgA deposits to the peripheral capillary loops shown by immunofluorescence. Only features (iii), (v), (vii) and (xi) proved to be independent prognostic indicators in the multivariate survivorship analysis (Cox regression model).

Entities:  

Mesh:

Year:  1986        PMID: 3749442

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  39 in total

1.  Quantitative analysis of glomeruli lesions in patients with mesangial proliferative glomerulonephritis.

Authors:  J Sun; Y Wang
Journal:  J Tongji Med Univ       Date:  1996

2.  Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy.

Authors:  L-L Liu; Y Jiang; L-N Wang; N Liu
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

3.  Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients.

Authors:  Y Pei; J Scholey; K Thai; M Suzuki; D Cattran
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

4.  Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

Authors:  Aron Chakera; Clare MacEwen; Shubha S Bellur; La-Or Chompuk; Daniel Lunn; Ian S D Roberts
Journal:  J Nephrol       Date:  2015-08-30       Impact factor: 3.902

5.  Renal histological changes in relation to renal function and urinary protein excretion in IgA nephropathy.

Authors:  U B Berg; S O Bohman; U Widstam-Attorps
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

Review 6.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

Review 7.  Recognition and management of IgA nephropathy.

Authors:  L S Ibels; A Z Gyory; R J Caterson; C A Pollock; J F Mahony; D A Waugh; S Coulshed
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

8.  Treatment of severe IgA nephropathy in children.

Authors:  S P Andreoli; J M Bergstein
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

9.  Histopathologic features aid in predicting risk for progression of IgA nephropathy.

Authors:  Michael Walsh; Aylin Sar; Diane Lee; Serdar Yilmaz; Hallgrimur Benediktsson; Braden Manns; Brenda Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

10.  Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center.

Authors:  Minako Koike; Takashi Takei; Keiko Uchida; Kazuho Honda; Takahito Moriyama; Shigeru Horita; Tetsuya Ogawa; Takumi Yoshida; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2008-02-21       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.